Development and Internal Validation of the Soluble ST2, Age, and Estimated Glomerular Filtration Rate–Heart Failure Score for Predicting 30-Day Major Adverse Cardiovascular Events After Heart Failure Hospitalization in a Two-Center Vietnamese Cohort: Prospective Cohort Study

An Viet Tran, Nguyen Khoi Quoc La, Van Anh Thi Phan, Bao The Nguyen, Hoa Thai Nguyen, Nhung Hong Thi Thai, Tho Anh Kieu Pham, Andrew Coristine · 2026

Read Development and Internal Validation of the Soluble ST2, Age, and Estimated Glomerular Filtration Rate–Heart Failure Score for Predicting 30-Day Major Adverse Cardiovascular Events After Heart Failure Hospitalization in a Two-Center Vietnamese Cohort: Prospective Cohort Study by An Viet Tran, Nguyen Khoi Quoc La, Van Anh Thi Phan, Bao The Nguyen, Hoa Thai Nguyen, Nhung Hong Thi Thai, Tho Anh Kieu Pham, Andrew Coristine (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13418553.txt.

Introduction

Tran and colleagues report a 2026 study from two hospitals in Vietnam on risk soon after heart failure care. They built a simple score, called SAGE-HF, to flag patients likely to die or return to hospital within 30 days of discharge. The score uses three items: a blood marker named sST2, age, and a standard measure of kidney function.

Within 30 days, 47 of the 218 patients died or were readmitted. Each score item linked to events on its own, and sST2 levels ran higher in patients than in people without heart failure. The score split patients into clear bands, with predicted event rates rising from low single digits to about six in ten at the top. Its accuracy held up under resampling checks. Clinics could use it to plan closer follow-up for high-risk patients.

Catalog record

CREATORAn Viet Tran, Nguyen Khoi Quoc La, Van Anh Thi Phan, Bao The Nguyen, Hoa Thai Nguyen, Nhung Hong Thi Thai, Tho Anh Kieu Pham, Andrew Coristine
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE49 KB
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13418553

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Development and Internal Validation of the Soluble ST2, Age, and Estimated Glomerular Filtration Rate–Heart Failure Score for Predicting 30-Day Major Adverse Cardiovascular Events After Heart Failure Hospitalization in a Two-Center Vietnamese Cohort: Prospective Cohort Study Authors: An Viet Tran, Nguyen Khoi Quoc La, Van Anh Thi Phan, Bao The Nguyen, Hoa Thai Nguyen, Nhung Hong Thi Thai, Tho Anh Kieu Pham, Andrew Coristine Published: 2026 ABSTRACT AbstractBackgroundPatients hospitalized for heart failure (HF) face a high-risk early postdischarge period.ObjectiveWe aimed to develop and internally validate the soluble ST2, age, and estimated glomerular filtration rate–heart failure (SAGE-HF) score, a simplified risk model incorporating soluble suppression of tumorigenicity 2 (sST2), age, and renal function, for predicting 30-day postdischarge major adverse cardiovascular events (MACE).MethodsThis two-center prospective cohort study included 218 patients hospitalized with acute decompensated heart failure (ADHF) and/or heart failure with reduced ejection fraction (HFrEF) and 59 non-HF controls in Vietnam (July 2025-January 2026). Serum sST2 concentrations were measured at admission using enzyme-linked immunosorbent assay and compared between the ADHF/HFrEF cohort and controls, with adjustment for clinical covariates. Among the ADHF/HFrEF cohort, the primary endpoint was 30-day MACE, defined as a composite of all-cause death or HF rehospitalization. Candidate predictors were considered based on clinical relevance, biological plausibility, and exploratory univariable associations, and prespecified parsimonious logistic regression models were evaluated using discrimination (area under the receiver operating characteristic curve [AUC]), calibration, Brier score, and Akaike information criterion. Internal validation was performed using 1000 bootstrap resamples, and model robustness was assessed using Firth penalized logistic regression. The SAGE-HF score was derived from the final model. All data were analyzed using the R environment (version 4.5.5; R Foundation for Statistical Computing).ResultsAmong 277 participants, sST2 concentrations were significantly higher in patients with HF than in non-HF controls after adjustment. Among 218 patients, 47 (21.6%) experienced 30-day MACE. In multivariable analysis, age (odds ratio [OR] 1.04 per year, 95% CI 1.01‐1.07; P=.02), sST2 (OR 1.06 per ng/mL, 95% CI 1.01‐1.11; P=.01), and estimated glomerular filtration rate (OR 0.98 per unit, 95% CI 0.97‐1.00; P=.02) were independently associated with MACE. The final model demonstrated acceptable discrimination (AUC 0.741, 95% CI 0.664‐0.819) and good calibration, with stable performance after bootstrap validation (corrected AUC 0.725). Firth analysis yielded consistent results. The SAGE-HF score showed progressive risk stratification, with predicted 30-day MACE ranging from 7.0% to 60.1% and maintained acceptable discrimination and calibration.ConclusionsThe SAGE-HF score, incorporating age, sST2, and estimated glomerular filtration rate, demonstrated acceptable performance for predicting 30-day MACE after HF hospitalization and may support early risk stratification, pending external validation. Introduction Heart failure (HF) is a major and growing global health problem, with substantial variation in epidemiology across regions and persistent gaps in data from developing countries [1,2]. After hospitalization for acute decompensation, patients enter a high-risk early postdischarge interval, often termed a “vulnerable phase,” during which adverse outcomes—including rehospitalization and death—cluster soon after discharge [3]. Indeed, approximately 25% of patients hospitalized with HF are readmitted within 30 days of discharge, and mortality during this period can approach 10% [4,5]. These early events are not only clinically important but also central to health-system quality initiatives and transitional-care pathways, motivating stronger tools for early postdischarge risk identification. Despite extensive effort, predicting early postdischarge events in HF remains challenging: readmissions arise from heterogeneous mechanisms and diagnoses, and many existing models show only modest performance or limited portability across settings [4,6]. Current guidelines emphasize guideline-directed medical therapy, careful discharge planning, and timely follow-up, but they do not provide a universally adopted, low-burden, biomarker-enhanced tool specifically optimized for very short-term postdischarge HF outcomes [7]. Identifying whether a small set of routinely available predictors, together with a biologically informative biomarker, can improve short-term risk stratification remains a practical clinical need. Soluble suppression of tumorigenicity 2 (sST2), part of the interleukin (IL)-33/ST2 axis, is mechanistically linked to myocardial stress, inflammation, fibrosis, and remodeling; circulating sST2 acts as a decoy receptor that neutralizes IL-33 signaling [8]. In acute and chronic HF, sST2 has repeatedly demonstrated prognostic value for mortality and HF hospitalization, including additive value beyond natriuretic peptides in several studies [9-12]. However, clinically usable short-term models that incorporate sST2 remain relatively limited, especially in Southeast Asian settings. Therefore, we conducted a two-center prospective cohort study to develop and internally validate a parsimonious model and simplified point score incorporating admission sST2, namely the soluble ST2, age, and estimated glomerular filtration rate–heart failure (SAGE-HF) score, to predict 30-day postdischarge major adverse cardiovascular events (MACE) after HF hospitalization. Methods Study Design and Population This prospective observational study was conducted at Thong Nhat Dong Nai General Hospital and Can Tho Central General Hospital between July 2025 and January 2026. The study population comprised patients hospitalized with acute decompensated heart failure (ADHF) and/or heart failure with reduced ejection fraction (HFrEF) who met the prespecified eligibility criteria. Patients were eligible if they were admitted with ADHF regardless of left ventricular ejection fraction (LVEF) phenotype and/or had HFrEF documented during the index hospitalization. Underlying HF was diagnosed by the treating cardiologists based on compatible symptoms and signs, echocardiographic assessment, and routine clinical investigations during the index hospitalization. ADHF was recorded when patients were admitted because of new or worsening symptoms and signs of HF requiring inpatient treatment. LVEF was assessed by transthoracic echocardiography during the index hospitalization and was used to classify HF phenotype as HFrEF, heart failure with mildly reduced ejection fraction (HFmrEF), or heart failure with preserved ejection fraction (HFpEF). For this study, HFrEF was defined as LVEF ≤40%, HFmrEF as LVEF 41% to 49%, and HFpEF as LVEF ≥50%. Patients with HFmrEF and HFpEF were included only if they were hospitalized with ADHF during the index hospitalization. Therefore, ADHF and HFrEF were not considered mutually exclusive categories. ADHF was considered a clinical presentation, whereas LVEF phenotype was considered an echocardiographic classification. Patients with end-stage chronic kidney disease (estimated glomerular filtration rate [eGFR]<15 mL/min/1.73 m²) or receiving dialysis, those with conditions known to affect sST2 levels, including systemic diseases such as lupus, rheumatoid arthritis, and chronic obstructive pulmonary disease, as well as those lost to follow-up, were excluded. Hospital admission and discharge decisions were made by the treating physicians according to routine clinical practice, and patients were discharged when they were considered clinically stable and suitable for outpatient follow-up. In addition, a non-HF comparison group was recruited for exploratory comparison of baseline characteristics and serum sST2 concentrations. These participants had no known history of HF based on medical record review and clinical history. They underwent clinical assessment to exclude HF, with routine electrocardiogram assessment as part of hospital evaluation. The absence of HF was further supported by N-terminal pro-B-type natriuretic peptide testing and transthoracic echocardiography. A total of 218 patients with ADHF and/or HFrEF and 59 non-HF controls were included in the final analysis. Ethical Considerations The study protocol was reviewed and approved by the Biomedical Research Ethics Committee of Can Tho University of Medicine and Pharmacy, Vietnam, for both participating centers. Ethical approval was granted for the study conducted at Can Tho Central General Hospital under approval number 25.326.HV/PCT-HĐĐĐ, dated June 30, 2025, and for the study conducted at Thong Nhat Dong Nai General Hospital under approval number 25.274.HV/PCT-HĐĐĐ, dated June 30, 2025. The study was conducted in accordance

Read the complete text